Advertisement
Singapore markets closed

  • Straits Times Index

    3,293.13
    +20.41 (+0.62%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • Dow

    38,503.69
    +263.71 (+0.69%)
     

  • Nasdaq

    15,696.64
    +245.33 (+1.59%)
     

  • Bitcoin USD

    66,348.12
    +49.24 (+0.07%)
     

  • CMC Crypto 200

    1,433.13
    +9.03 (+0.63%)
     

  • FTSE 100

    8,085.11
    +40.30 (+0.50%)
     

  • Gold

    2,328.90
    -13.20 (-0.56%)
     

  • Crude Oil

    82.87
    -0.49 (-0.59%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     

  • Jakarta Composite Index

    7,174.53
    +63.72 (+0.90%)
     

  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

Indivior lifts FY profit view on slower erosion of Suboxone market share

Reuters

(Reuters) - Drugmaker Indivior Plc on Thursday raised its profit and revenue guidance for the full year as its blockbuster opioid drug Suboxone lost market share at a lower pace than expected, bolstering its first-half performance.

The company, spun off from Reckitt Benckiser in 2014, expects net income for 2019 in the range of $80 million to $130 million, up from a prior expectation of between a loss of $40 million and $10 million.

It also said its generic version of branded Suboxone was performing well.

Separately, Reckitt said it would pay up to $1.4 billion to resolve all U.S. federal investigations related to Indivior.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)